National Coverage Analysis (NCA) Tracking Sheet

Preexposure Prophylaxis (PrEP) Using Antiretroviral Therapy to Prevent Human Immunodeficiency Virus (HIV) Infection

CAG-00464N

Issue

Per Section 1861(ddd) of the Social Security Act and implementing regulations at 42 CFR 410.64, CMS may cover "additional preventive services," if it determines through the national coverage determination (NCD) process that the service is recommended with a grade A (strongly recommends) or grade B (recommends) rating by the United States Preventive Services Task Force (USPSTF) and that it also meets certain other requirements.

The USPSTF recently published (December 13, 2022) a draft recommendation with a grade A for prescribing PrEP with effective antiretroviral therapy to persons who are at increased risk of HIV acquisition to decrease the risk of acquiring HIV infection (https://www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/prevention-human-immunodeficiency-virus-hiv-infection-prep). This draft is an update to their 2019 recommendation.

CMS received a complete, formal request to consider an NCD for coverage of PrEP using antiretrovirals for persons at high risk of HIV acquisition.

CMS is soliciting public comment relevant to the consideration. We are particularly interested in comments that include scientific evidence and that address the breadth of the request.

Benefit Category

Additional Preventive Services

Requestor Information

Requestor NameRequestor Letter
ViiV Healthcare View Letter

Important Dates

Formal Request Accepted and Review Initiated
01/12/2023
Expected NCA Completion Date
10/10/2023
Public Comment Period
01/12/2023 - 02/11/2023
Proposed Decision Memo Due Date
07/12/2023
Comments for this NCA
View Public Comments

Contacts

Lead Analysts
Rachel Katonak
Rachel.katonak@cms.hhs.gov
410-786-8564
Lead Medical Officers
Carl Li, M.D.

Actions Taken

January 12, 2023

CMS initiates this national coverage analysis for Preexposure Prophylaxis (PrEP) Using Antiretroviral Therapy to Prevent Human Immunodeficiency Virus (HIV) Infection. The initial 30-day public comment period begins with this posting date, and ends after 30 calendar days. CMS considers all public comments, and is particularly interested in clinical studies and other scientific information relevant to the topic under review.

Instructions on submitting comments can be found at: http://www.cms.gov/Medicare/Coverage/InfoExchange/publiccomments.html.

To submit a comment, please use the blue "Comment" button at the top of the page. Enter comments directly into the “Submit A Public Comment” webpage.